The US-based Pancreatic Cancer Action Network informs its members about Immunovia's blood test IMMray PanCan-do
The Pancreatic Cancer Action Network (PanCAN) is the largest ever patient group for pancreasis in the United States today announced that its global headquarters, IMMray, has publicly informed its constituents about the test I
PanCAN underlines that IMMrayTM PanCan-d is the first test that is specifically for pancreatic cancer and is available to people at high risk of disease due to family history or genetic alterations. PanCAN describes that the test is requested through a doctor, who will also receive the tests results from Immunovia, Inc. Interested people can contact PanCan Patient Services, which provides free information and answers questions about the IMMray
"Pancreatic cancer is a difficult disease. The general population doesn't have an early detection test, so there's very few treatment options, which means that progress is getting better. The Immunovia IMMray test is an important step for some patients to be diagnosed earlier, have more treatment options and live longer, said Julie Fleshman, JD, MBA, President and CEO of Pancreatic Cancer Action
"Panancan is of tremendous value to raise awareness about Immunovia, Inc.'s blood test IMMrayTM PanCan-d in the US. PanCAN is reaching a very wide audience and speaks directly to those in the familial/hereditary risk group that need to be given the chance to get tested," said Patrik Dahlen, Managing Director of Immunovia
IMMrayTM PanCan-d was launched in August in the US by Immunovia Inc., and currently available in all states except New York, California, Maryland, Pennsylvania and Rhode Island.
For more information, please contact: Patrik Dahlen, CEO ImmunoviaEmail: [email protected] Tel: +46 73 376 76 64. About Immunovia Immunovia AB is a diagnostic company that is developing and commercializing highly accurate blood tests for the early detection of diseases and diseases by using the proprietary IMMray platform. Tests are based on antibodies biomarkers and bio So, forming a unique "disease biomarker signature".
The company was founded in 2007, in the midst of cancer studies and a successful career in Immuntechnology at Lund University and CREATE Health Cancer Center, Sweden.
The first product, IMMrayTM PanCan-d, is being evaluated in some of the world's largest clinical trials for pancreatic cancer, PanFAM-1, panSYM 1 and PanDIA-1.
Immunovia was founded in Marlborough, Massachusetts in 2017. In 2017, Immunoa Inc. was established in Massachusetts. The IMMray PanCan-d test, the first blood-based test in the market to detect pancreatic cancer, is exclusively available in a lab. To get more information, visit www.immunoviainc The European launch plan will be communicated in the second half of 2021.
The shares of Immunovia (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit www.immunovia.com.
Cision has brought this information to you by http://news.cision.com. Cider has the following information.
Imm,c3414521 - www.news.cision.com/immunovia-ab/r/the-us-based-pancreatic-cancer-action-network-informs
The following files are available for download:
PDF PDF release release.
SOURCE Immunovia AB SURCE SKIRSC RI DRIVE SESSION SURE A BSIF BANKS AVEC BI-SOURCES SUMBER YARDS